Contact Information
Address(Office)E12-4007Kin Yip TAM
Phone(Office)8822 4988
(Lab)8822 2907
Fax8822 2314
D.Phil.University of Oxford (1996)
M.Phil.Hong Kong Polytechnic (1992)
B.Sc.Hong Kong Baptist College (1990)
2013-presentAssociate Professor, Faculty of Health Sciences, University of Macau
2011 – 2012DMPK Design Leader, AstraZeneca
2004 – 2011Associate Principal Scientist, AstraZeneca
2001 – 2004Senior Scientist, AstraZenenca
1996– 2001Research Chemist, Sirius Analytical Ltd.
Research Interests
  • Development of small molecule inhibitors targeting cancer metabolism and Alzheimer’s disease
  • Pharmacokinetic and chemical optimizations of drug candidates
  • High throughput compound profiling for supporting drug discovery
Representative Publications
  1. W. Zhang, Xiaohui Hu, W. Zhou, K.Y. Tam, Liquid Chromatography-Tandem Mass Spectrometry Method Revealed that Lung Cancer Cells Exhibited Distinct Metabolite Profiles upon the Treatment with Different Pyruvate Dehydrogenase Kinase Inhibitors, Journal of Proteome Research, in press. DOI: 10.1021/acs.jproteome.8b00184
  2. S.L. Zhang, Z. Yang, X. Hu, H. Chakravarty, K.Y. Tam, Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1, European journal of pharmaceutical sciences, 123, 43-55, 2018.
  3. S.L. Zhang, Y. He, K.Y. Tam, Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors, Drug discovery today, 23, 1407-1415, 2018.
  4. Z. Yang, K.Y. Tam, Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes, International Journal of Biological Sciences, 14, 204-216, 2018.
  5. X. Wu, J. Kosaraju, W. Zhou, K.Y. Tam, SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer’s disease, Neuropharmacology, 131, 351-363, 2018.
  6. W. Zhou, X. Hu, K.Y. Tam, Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates, Scientific Reports, 7, 16368, 2017.
  7. W. Zhang, S.L. Zhang, X. Hu, K.Y. Tam, Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect, European journal of pharmaceutical sciences, 110, 93-100, 2017.
  8. S.L. Zhang, W. Zhang, Z. Yang, X. Hu, K.Y. Tam, Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells, European journal of pharmaceutical sciences, 110, 87-92, 2017.
  9. Z. Yang, X. Hu, S. Zhang, W. Zhang, K.Y. Tam, Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells, European Journal of Pharmacology, 815, 80-87, 2017.
  10. X. Wu, J. Kosaraju, W. Zhou, K.Y. Tam, Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer’s Disease, ACS Chemical Neuroscience, 8, 676-685, 2017.
  11. X. Wu, J. Kosaraju, K.Y. Tam, SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3beta activity in SH-SY5Y cells, European journal of pharmaceutical sciences, 110, 101-108, 2017.
  12. J. Kosaraju, R.M.D. Holsinger, L. Guo, K.Y. Tam, Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease, Molecular Neurobiology, 54, 6074-6084, 2017.
  13. X. Hu, K.Y. Tam, Association of vancomycin with lipid vesicles, ADMET & DMPK, 5, 183, 2017.
  14. X. Hu, K. Tam, Biomembrane mimics and their roles in anti-bacterial drug discovery, ADMET & DMPK, 5, 9, 2017.
  15. W. Zhou, X. Wu, J. Li, X. Hu, K.Y. Tam, Quantification of permanent positively charged compounds in plasma using one-step dilution to reduce matrix effect in MS, Bioanalysis, 8, 497-509, 2016.
  16. S.L. Zhang, W. Zhang, Q.P. Xiao, Z. Yang, X.H. Hu, Z.Y. Wei, K.Y. Tam, Development of dichloroacetamide pyrimidines as pyruvate dehydrogenase kinase inhibitors to reduce cancer cell growth: synthesis and biological evaluation, RSC Advance, 6, 78762-78767, 2016.
  17. S.L. Zhang, X. Hu, W. Zhang, K.Y. Tam, Unexpected Discovery of Dichloroacetate Derived Adenosine Triphosphate Competitors Targeting Pyruvate Dehydrogenase Kinase To Inhibit Cancer Proliferation, Journal of medicinal chemistry, 59, 3562-3568, 2016.
  18. Z. Yang, K.Y. Tam, Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines, European Journal of Pharmacology, 789, 458-467, 2016.
  19. G.J. Peters, K. Tam, ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors, ADMET & DMPK, 4, 182-185, 2016.
  20. W. Zhang, S.L. Zhang, X. Hu, K.Y. Tam, Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?, International Journal of Biological Sciences, 11, 1390-1400, 2015.
  21. S.L. Zhang, X. Hu, W. Zhang, H. Yao, K.Y. Tam, Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents, Drug discovery today, 20, 1112-1119, 2015.
  22. X. Wu, J. Li, W. Zhou, K. Tam, Animal models for Alzheimer’s disease: a focused review of transgenic rodent models and behavioral assessment methods, ADMET & DMPK, 3, 242-253, 2015.
  23. J. Li, W. Zhou, X. Wu, K. Tam, Chemical and Physical Approaches for the Treatment of Alzheimer’s Disease, ADMET & DMPK, 3, 216-234, 2015.
  24. D. Dohoda, K. Tsinman, O. Tsinman, H. Wang, K.Y. Tam, Spectrophotometric pKa determination of ionizable pharmaceuticals: Resolution of molecules with weak pH-dependent spectral shift, Journal of pharmaceutical and biomedical analysis, 114, 88-96, 2015.
  25. M. Velicky, K.Y. Tam, RA. Dryfe, Mechanism of ion transfer in supported liquid membrane systems: electrochemical control over membrane distribution, Analytical chemistry, 86, 435-442, 2014.
  26. S.L. Zhang, H. Yao, C. Wang, K.Y. Tam, Study the interactions between human serum albumin and two antifungal drugs: fluconazole and its analogue DTP, Bioorganic & medicinal chemistry letters, 24, 4963-4968, 2014.
  27. W. Zhang, C. Wang, K.Y. Tam, Predicting the minimal inhibitory concentration of fluoroquinolones for Escherichia coli using an accumulation model, Bio-medical materials and engineering. 24, 3745-3751, 2014.
  28. K. Tam, Estimating the “First in human” dose – a revisit with particular emphasis on oncology drugs, ADMET & DMPK, 1, 63-75, 2013.
  29. K. Tam, The Roles of Doxorubicin in Hepatocellular Carcinoma, ADMET & DMPK, 1, 29-44, 2013.
  30. K. Tam, Close relationships between in vitro ADMET and DMPK researches in pre-clinical drug discovery, ADMET & DMPK, 1, 1-2, 2013.
Full Publications List
Research Grants
2018-2021Development of metabolic inhibitor for the treatment of non-small-cell lung carcinoma, MOP 1,460,000
2017-2020Novel Multi-targeting compounds for the treatment of Alzheimer´s disease, MOP 540,000
2015-2018Combination treatment with arginine depleting enzyme and metabolic inhibitor in preclinical cancer models, MOP 1,500,000
2014-2017Preclinical optimization of Aβ peptides aggregation inhibitors as potential drug candidates for the treatment of Alzheimer’s disease, MOP 1,456,000
2013-2015A study of the interactions between vancomycin, nafcillin and biomimetic artificial membranes, MOP 125,000
  • S.C. Tsang, K.Y. Tam, X. Gao, “Composite Nanoparticles”, PCT WO2005007284, 27th Jan 2005.
2009AstraZeneca Regional Innovation Award
2008AstraZeneca Publication Award
Professional Recognition
2013Editor-in-chief, ADMET & DMPK (Scopus and ESCI indexed open access journal)
2009AstraZeneca Regional Innovation Award (for the contribution to a discovery project using a pro-drug delivery approach)
2008AstraZeneca Publication Award (Cancer and Infection Chemistry)
2004Fellow of the Royal Society of Chemistry, UK
1999Chartered Chemist and member of the Royal Society of Chemistry, UK